The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Biodegradable Long-Circulating Polymeric Nanospheres
Gref, R., Minamitake, Y., Peracchia, M. T., Trubetskoy, V., Torchilin, V., & Langer, R. (1994) · Science · doi:10.1126/science.8128245 · Cited by 2,920
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Maeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376
A review of stimuli-responsive nanocarriers for drug and gene delivery
Ganta, S., Devalapally, H., Shahiwala, A., & Amiji, M. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.017 · Cited by 2,155
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
Klibanov, A. L., Maruyama, K., Torchilin, V. P., & Huang, L. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)81016-h · Cited by 2,027
Targeted drug delivery to tumors: Myths, reality and possibility
Bae, Y. H., & Park, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.001 · Cited by 1,935
Huh, A. J., & Kwon, Y. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.002 · Cited by 1,864
Mann, R., Mulligan, R. C., & Baltimore, D. (1983) · Cell · doi:10.1016/0092-8674(83)90344-6 · Cited by 1,805
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,730
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., & Jain, R. K. (1995) · PubMed · Cited by 1,711
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Self-citationMultifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities
Cheng, Z., Al Zaki, A., Hui, J. Z., Muzykantov, V. R., & Tsourkas, A. (2012) · Science · doi:10.1126/science.1226338 · Cited by 1,322
Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,274
Formulation of functionalized PLGA-PEG Nanoparticles for in vivo targeted drug delivery
Cheng, J., Teply, B. A., Sherifi, I., Sung, J., Luther, G., Gu, F. X., Levy-Nissenbaum, E., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.09.047 · Cited by 1,273
Hrkach, J., Von Hoff, D., Ali, M. M., Andrianova, E., Auer, J., Campbell, T., De Witt, D., Figa, M., Figueiredo, M., Horhota, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003651 · Cited by 1,147
Kirpotin, D. B., Drummond, D. C., Shao, Y., Shalaby, M. R., Hong, K., Nielsen, U. B., Marks, J. D., Benz, C. C., & Park, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4199 · Cited by 1,125
The big picture on nanomedicine: the state of investigational and approved nanomedicine products
Etheridge, M. L., Campbell, S. A., Erdman, A. G., Haynes, C. L., Wolf, S. M., & McCullough, J. (2013) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2012.05.013 · Cited by 1,088
Nanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 981
Davis, M. E. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900015y · Cited by 977
Nanoparticle-Aptamer Bioconjugates
Farokhzad, O. C., Jon, S., Khademhosseini, A., Tran, T.-N. T., LaVan, D. A., & Langer, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2550 · Cited by 897
RNA interference in the clinic: challenges and future directions
Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G., & Sood, A. K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2966 · Cited by 820
The transferrin receptor and the targeted delivery of therapeutic agents against cancer
Daniels, T. R., Bernabeu, E., Rodríguez, J. A., Patel, S., Kozman, M., Chiappetta, D. A., Holler, E., Ljubimova, J. Y., Helguera, G., & Penichet, M. L. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.07.016 · Cited by 807
Bartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707461104 · Cited by 803
Antibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 770
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G. T., Shalaby, R., Baselga, J. M., Shao, Y. Y., Nielsen, U. B., Marks, J. D., Moore, D. H., et al. (2002) · Clinical Cancer Research · Cited by 766
The origins and evolution of “controlled” drug delivery systems
Hoffman, A. S. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.08.012 · Cited by 738
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers
Gu, F., Zhang, L., Teply, B. A., Mann, N., Wang, A., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711714105 · Cited by 715
Ibrahim, N. K., Desai, N. P., Legha, S. S., Soon‐Shiong, P., Theriault, R. L., Rivera, E., Esmaeli, B., Ring, S. E., Bedikian, A. Y., Hortobágyi, G. N., et al. (2002) · PubMed · Cited by 705
Liposomes for the sustained drug release in vivo
Blume, G., & Cevc, G. (1990) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(90)90440-y · Cited by 698
Oxaliplatin: A review of preclinical and clinical studies
Raymond, E., Chaney, S. G., Taamma, A., & Cvitkovic, E. (1998) · Annals of Oncology · doi:10.1023/a:1008213732429 · Cited by 643
Dams, E. T. M., Laverman, P., Oyen, W. J. G., Storm, G., Scherphof, G. L., van der Meer, J. W. M., Corstens, F. H. M., & Boerman, O. C. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35391-1 · Cited by 607
Self-citationHu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E., & Triche, T. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0565 · Cited by 567
Lupold, S. E., Hicke, B. J., Lin, Y. H., & Coffey, D. S. (2002) · PubMed · Cited by 566
Sheddable Coatings for Long-Circulating Nanoparticles
Romberg, B., Hennink, W. E., & Storm, G. (2008) · Pharmaceutical Research · doi:10.1007/s11095-007-9348-7 · Cited by 555
Self-citationNanotechnological advances for the delivery of cns therapeutics.
Wong, H. L., Wu, X. Y., & Bendayan, R. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.10.007 · Cited by 488
Uziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F. M., & Gabizon, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1777 · Cited by 477
Self-Assembled Targeted Nanoparticles: Evolution of Technologies and Bench to Bedside Translation
Shi, J., Xiao, Z., Kamaly, N., & Farokhzad, O. C. (2011) · Accounts of Chemical Research · doi:10.1021/ar200054n · Cited by 476
Prostate-specific membrane antigen is produced in tumor-associated neovasculature.
Chang, S. S., O’Keefe, D. S., Bacich, D. J., Reuter, V. E., Heston, W. D. W., & Gaudin, P. B. (1999) · PubMed · Cited by 471
Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy
Gabizon, A. A. (2001) · Cancer Investigation · doi:10.1081/cnv-100103136 · Cited by 458
Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis
Murphy, E. A., Majeti, B. K., Barnes, L. A., Makale, M., Weis, S. M., Lutu-Fuga, K., Wrasidlo, W., & Cheresh, D. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803728105 · Cited by 455
Clinical pharmacokinetics of oxaliplatin: a critical review.
Graham, M. A., Lockwood, G. F., Greenslade, D., Brienza, S., Bayssas, M., & Gamelin, E. (2000) · PubMed · Cited by 455
Kirpotin, D., Park, J. W., Hong, K., Zalipsky, S., Li, W.-L., Carter, P., Benz, C. C., & Papahadjopoulos, D. (1997) · Biochemistry · doi:10.1021/bi962148u · Cited by 439
Perspectives and opportunities for nanomedicine in the management of atherosclerosis
Lobatto, M. E., Fuster, V., Fayad, Z. A., & Mulder, W. J. M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3578 · Cited by 423
Analysis on the current status of targeted drug delivery to tumors
Kwon, I. K., Lee, S. C., Han, B., & Park, K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.07.010 · Cited by 404
Nanoparticle Characterization: State of the Art, Challenges, and Emerging Technologies
Cho, E. J., Holback, H., Liu, K. C., Abouelmagd, S. A., Park, J., & Yeo, Y. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300697h · Cited by 382
Mamot, C., Drummond, D. C., Noble, C. O., Kallab, V., Guo, Z., Hong, K., Kirpotin, D. B., & Park, J. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1093 · Cited by 382
Heidel, J. D., Yu, Z., Liu, J. Y.-C., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701458104 · Cited by 382
Transferrin-Containing, Cyclodextrin Polymer-Based Particles for Tumor-Targeted Gene Delivery
Bellocq, N. C., Pun, S. H., Jensen, G. S., & Davis, M. E. (2003) · Bioconjugate Chemistry · doi:10.1021/bc034125f · Cited by 350
Tumor targeting using anti-her2 immunoliposomes
Park, J. W., Kirpotin, D. B., Hong, K., Shalaby, R., Shao, Y., Nielsen, U. B., Marks, J. D., Papahadjopoulos, D., & Benz, C. C. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00315-7 · Cited by 335
Polymeric Antitumor Agents on a Molecular and on a Cellular Level?
Gros, L., Ringsdorf, H., & Schupp, H. (1981) · Angewandte Chemie International Edition in English · doi:10.1002/anie.198103051 · Cited by 318
Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin
Schiffelers, R. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00240-2 · Cited by 310
MacDiarmid, J. A., Mugridge, N. B., Weiss, J. C., Phillips, L., Burn, A. L., Paulin, R. P., Haasdyk, J. E., Dickson, K.-A., Brahmbhatt, V. N., Pattison, S. T., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.03.012 · Cited by 307
Nanotechnology applied to overcome tumor drug resistance
Gao, Z., Zhang, L., & Sun, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.051 · Cited by 303
Laverman, P., Carstens, M. G., Boerman, O. C., Th. M. Dams, E., Oyen, W. J. G., van Rooijen, N., Corstens, F. H. M., & Storm, G. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29419-2 · Cited by 298
Self-citationMaresca, K. P., Hillier, S. M., Femia, F. J., Keith, D., Barone, C., Joyal, J. L., Zimmerman, C. N., Kozikowski, A. P., Barrett, J. A., Eckelman, W. C., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800994j · Cited by 295
(2004) · The Women's Oncology Review · doi:10.3109/14733400410001727592 · Cited by 288
Physicochemical and Biological Characterization of Targeted, Nucleic Acid-Containing Nanoparticles
Bartlett, D. W., & Davis, M. E. (2007) · Bioconjugate Chemistry · doi:10.1021/bc0603539 · Cited by 283
MacDiarmid, J. A., Amaro-Mugridge, N. B., Madrid-Weiss, J., Sedliarou, I., Wetzel, S., Kochar, K., Brahmbhatt, V. N., Phillips, L., Pattison, S. T., Petti, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1547 · Cited by 272
Development of anti-p185HER2 immunoliposomes for cancer therapy.
Park, J. W., Hong, K., Carter, P., Asgari, H., Guo, L. Y., Keller, G. A., Wirth, C., Shalaby, R., Kotts, C., & Wood, W. I. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1327 · Cited by 258
Ishida, O., Maruyama, K., Tanahashi, H., Iwatsuru, M., Sasaki, K., Eriguchi, M., & Yanagie, H. (2001) · Pharmaceutical Research · doi:10.1023/a:1010960900254 · Cited by 257
Targeting Dendritic Cells with Antigen-Containing Liposomes
van Broekhoven, C. L., Parish, C. R., Demangel, C., Britton, W. J., & Altin, J. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0138 · Cited by 256
Matsumura, Y., Gotoh, M., Muro, K., Yamada, Y., Shirao, K., Shimada, Y., Okuwa, M., Matsumoto, S., Miyata, Y., Ohkura, H., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh092 · Cited by 253
Effective anti-tumor activity of oxaliplatin encapsulated in transferrin–PEG-liposome
Suzuki, R., Takizawa, T., Kuwata, Y., Mutoh, M., Ishiguro, N., Utoguchi, N., Shinohara, A., Eriguchi, M., Yanagie, H., & Maruyama, K. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.06.010 · Cited by 250
Mamot, C., Ritschard, R., Wicki, A., Stehle, G., Dieterle, T., Bubendorf, L., Hilker, C., Deuster, S., Herrmann, R., & Rochlitz, C. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70476-x · Cited by 244
Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes.
Xu, L., Huang, C., Huang, W., Tang, W., Rait, A. S., Yin, Y. Z., Cruz, I., Xiang, L., Pirollo, K. F., & Chang, E. H. (2002) · PubMed · Cited by 243
Future directions of liposome- and immunoliposome-based cancer therapeutics
Park, J. W., Benz, C. C., & Martin, F. J. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.08.009 · Cited by 240
Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors
Senzer, N., Nemunaitis, J., Nemunaitis, D., Bedell, C., Edelman, G., Barve, M., Nunan, R., Pirollo, K. F., Rait, A., & Chang, E. H. (2013) · Molecular Therapy · doi:10.1038/mt.2013.32 · Cited by 236
Antibody–drug conjugates: Basic concepts, examples and future perspectives
Casi, G., & Neri, D. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.026 · Cited by 210
Nanotechnology—novel therapeutics for CNS disorders
Srikanth, M., & Kessler, J. A. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.76 · Cited by 198
Couvreur, P., Kante, B., Roland, M., & Speiser, P. (1979) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600681215 · Cited by 186
Unbounding the future: The nanotechnology revolution
(1993) · Precision Engineering · doi:10.1016/0141-6359(93)90208-r · Cited by 176
Clinical translation of nanomedicines
Svenson, S. (2012) · Current Opinion in Solid State and Materials Science · doi:10.1016/j.cossms.2012.10.001 · Cited by 175
Moghimi, S. M., Andersen, A. J., Hashemi, S. H., Lettiero, B., Ahmadvand, D., Hunter, A. C., Andresen, T. L., Hamad, I., & Szebeni, J. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.003 · Cited by 167
Heidel, J. D., Liu, J. Y.-C., Yen, Y., Zhou, B., Heale, B. S. E., Rossi, J. J., Bartlett, D. W., & Davis, M. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2218 · Cited by 160
Development of ligand-targeted liposomes for cancer therapy
Noble, C. O., Kirpotin, D. B., Hayes, M. E., Mamot, C., Hong, K., Park, J. W., Benz, C. C., Marks, J. D., & Drummond, D. C. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.4.335 · Cited by 157
Maindrault‐Gœbel, F., de Gramont, A., Louvet, C., André, T., Carola, É., Mabro, M., Artru, P., Gilles-Amar, V., Lotz, J., Izrael, V., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00068-5 · Cited by 153
Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv
Xu, L., Tang, W., Huang, C., Alexander, W., Xiang, L., Pirollo, K. F., Rait, A. S., & Chang, E. H. (2001) · Molecular Medicine · doi:10.1007/bf03401962 · Cited by 150
Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy
Talelli, M., Oliveira, S., Rijcken, C. J. F., Pieters, E. H. E., Etrych, T., Ulbrich, K., van Nostrum, R., Storm, G., Hennink, W. E., & Lammers, T. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.064 · Cited by 132
Self-citationAntibody–drug conjugates – a perfect synergy
Adair, J. R., Howard, P. W., Hartley, J. A., Williams, D. G., & Chester, K. A. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.693473 · Cited by 120
(2004) · The Women s Oncology Review · doi:10.1080/14733400410001727592 · Cited by 120
Unbounding the future: the nanotechnology revolution
(1992) · Choice Reviews Online · doi:10.5860/choice.29-3855 · Cited by 105
Overview of Ribonucleotide Reductase Inhibitors: An Appealing Target in Anti-Tumour Therapy
Cerqueira, N. M. F. S. A., Pereira, S. R., Fernandes, P. A., & Ramos, M. J. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867054020981 · Cited by 104
Drug targeting systems for inflammatory disease: One for all, all for one
Crielaard, B. J., Lammers, T., Schiffelers, R. M., & Storm, G. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.014 · Cited by 101
Self-citationMinicells: Versatile vectors for targeted drug or si/shRNA cancer therapy
MacDiarmid, J. A., & Brahmbhatt, H. N. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.04.008 · Cited by 94
Liposomal vaccines—targeting the delivery of antigen
Altin, J. G., & Parish, C. R. (2006) · Methods · doi:10.1016/j.ymeth.2006.05.027 · Cited by 91
Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth
Rahman, M. A., Amin, A. R. M. R., Wang, X., Zuckerman, J. E., Choi, C. H. J., Zhou, B., Wang, D., Nannapaneni, S., Koenig, L., Chen, Z., et al. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.045 · Cited by 88
Xu, L., Pirollo, K. F., & Chang, E. H. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.4-467 · Cited by 88
Nellis, D. F., Ekstrom, D. L., Kirpotin, D. B., Zhu, J., Andersson, R., Broadt, T. L., Ouellette, T. F., Perkins, S. C., Roach, J. M., Drummond, D. C., et al. (2005) · Biotechnology Progress · doi:10.1021/bp049840y · Cited by 88
A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene
Yu, W. H., Pirollo, K. F., Rait, A. S., Yu, B., Xiang, L., Huang, W.-Q., Zhou, Q., Ertem, G., & Chang, E. H. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302304 · Cited by 86
Nellis, D. F., Giardina, S. L., Janini, G. M., Shenoy, S. R., Marks, J. D., Tsai, R. M., Drummond, D. C., Hong, K., Park, J. W., Ouellette, T. F., et al. (2005) · Biotechnology Progress · doi:10.1021/bp049839z · Cited by 85
A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin
Sankhala, K. K., Mita, A. C., Adinin, R., Wood, L. M., Beeram, M., Bullock, S., Yamagata, N., Matsuno, K., Fujisawa, T., & Phan, A. T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.2535 · Cited by 84
Chawla, S. P., Chua, V. S., Fernandez, L., Quon, D., Blackwelder, W. C., Gordon, E. M., & Hall, F. L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.228 · Cited by 81
Pinzon-Daza, M., Campia, I., Kopecka, J., Garzon, R., Ghigo, D., & Rigant, C. (2013) · Current Drug Metabolism · doi:10.2174/1389200211314060001 · Cited by 81
Chawla, S. P., Chua, V. S., Fernandez, L., Quon, D. V. K., Saralou, A., Blackwelder, W. C., Hall, F. L., & Gordon, E. M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.126 · Cited by 79
Rexin-G, a targeted genetic medicine for cancer
Gordon, E. M., & Hall, F. L. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.481666 · Cited by 79
Hamaguchi, T., Matsumura, Y., Nakanishi, Y., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Niki, H., Hosokawa, S., Tagawa, T., et al. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02495.x · Cited by 74
Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner
Hosokawa, S., Tagawa, T., Niki, H., Hirakawa, Y., Nohga, K., & Nagaike, K. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601341 · Cited by 72
Hendriks, B. S., Klinz, S. G., Reynolds, J. G., Espelin, C. W., Gaddy, D. F., & Wickham, T. J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0180 · Cited by 64
Gordon, E. M., Chen, Z. H., Liu, L., Whitley, M., Liu, L., Wei, D., Groshen, S. G., Hinton, D. R., Anderson, W. F., Beart, R. W., et al. (2001) · Human Gene Therapy · doi:10.1089/104303401750061258 · Cited by 61
Enhanced tumor cell growth suppression by an N-terminal truncated retinoblastoma protein.
Xu, H., Xu, K., Zhou, Y., Li, J. L. Y., Benedict, W. F., & Hu, S. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9837 · Cited by 58
Pirollo, K. F., Rait, A. S., Zhou, Q., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1951 · Cited by 56
Mamot, C., Ritschard, R., WICKI, A. N., Küng, W., Schuller, J. C., Herrmann, R., & Rochlitz, C. F. (2012) · Journal of drug targeting · doi:10.3109/1061186x.2012.680960 · Cited by 52
Galanis, E., Carlson, S. K., Foster, N. R., Lowe, V. J., Quevedo, F., McWilliams, R. R., Grothey, A. F., Jatoi, A., Alberts, S. R., & Rubin, J. (2008) · Molecular Therapy · doi:10.1038/mt.2008.29 · Cited by 50
Nicotine vaccines to treat tobacco dependence
Goniewicz, M. L., & Delijewski, M. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.22060 · Cited by 49
Zhang, X., Multani, A. S., Zhou, J., Shay, J. W., McConkey, D. J., Dong, L., Kim, C.-S., Rosser, C. J., Pathak, S., & Benedict, W. F. (2003) · PubMed · Cited by 44
Pathotropic nanoparticles for cancer gene therapy Rexin-G™ IV: Three-year clinical experience
Gordon, E. M., Lopez, F., Cornelio, G. H., Lorenzo, C., Levy, J. P., Reed, R. A., Liu, L., Bruckner, H. W., & Hall, F. L. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.5.1053 · Cited by 41
Senzer, N. N., Matsuno, K., Yamagata, N., Fujisawa, T., Wasserman, E., Sutherland, W., Sharma, S., & Phan, A. T. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-09-c36 · Cited by 40
Münster, P. N., Miller, K. D., Krop, I. E., Dhindsa, N., Reynolds, J., Geretti, E., Niyikiza, C., Nielsen, U. B., Hendriks, B. S., Wickham, T. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.tps663 · Cited by 23
Wickham, T. J., & Futch, K. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-p5-18-09 · Cited by 20
The ‘timely’ development of Rexin-G: First targeted injectable gene vector (Review)
Gordon, ⁄. (2009) · International Journal of Oncology · doi:10.3892/ijo_00000332 · Cited by 19
Pittet, L. A., Altreuter, D. H., Ilyinskii, P. O., Fraser, C., Gao, Y., Baldwin, S., Keegan, M., Johnston, L. P. M., & Kishimoto, T. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.188.supp.75.11 · Cited by 17
Receptor-mediated delivery of drugs across the blood-brain barrier
Pieter, G. (2010) · Frontiers in Pharmacology · doi:10.3389/conf.fphar.2010.02.00025 · Cited by 14
Wickham, T., Reynolds, J., Drummond, D. C., Kirpotin, D. B., Lahdenranta, J., Leonard, S., Geretti, E., Lee, H. H., Klinz, S. G., Hendriks, B. S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-p3-14-09 · Cited by 8
Cited by
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Self-citation
Metadata
- Authors
- van der Meel, R., Vehmeijer, L. J. C., Kok, R. J., Storm, G., & van Gaal, E. V. B.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 65
- Issue
- 10
- Pages
- 1284-1298
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2129144690
- Cited by
- 398
- References
- 124
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.